Sandoz Group AG (SDZ.SW) Stock Analysis & Winston Score

Sandoz Group AG is a Swiss pharmaceutical company that makes generic and biosimilar medicines. Generic drugs are cheaper copies of brand-name medications whose patents have expired, while biosimilars are lower-cost versions of complex biological drugs. Sandoz sells these products to hospitals, pharmacies, and healthcare systems around the world, making it one of the largest generic and biosimilar drugmakers globally after it was spun off from Novartis in 2023. Sandoz earns money by manufacturing and selling a large volume of medicines at competitive prices across more than 100 countries, with strong presence in Europe and North America. Its competitive edge comes from its scale, its manufacturing expertise, and its growing biosimilars portfolio, which is harder for rivals to copy than standard generics. The key growth driver is expanding biosimilar sales as more high-cost biological drugs lose patent protection, though pricing pressure in the generic drug market remains a persistent risk to profit margins.